Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.

dc.contributor.authorPotrony Mateu, Míriam
dc.contributor.authorBadenas Orquin, Celia
dc.contributor.authorNaerhuyzen, Bénédicte
dc.contributor.authorAguilera, Paula
dc.contributor.authorPuig Butillé, Joan Anton
dc.contributor.authorTell Martí, Gemma
dc.contributor.authorDíaz Lorca, Maria Alba
dc.contributor.authorCarrera Álvarez, Cristina
dc.contributor.authorAlós i Hernández, Llúcia
dc.contributor.authorDelahaye, Nicolas
dc.contributor.authorMalvehy, J. (Josep)
dc.contributor.authorPuig i Sardà, Susana
dc.date.accessioned2017-04-13T12:03:13Z
dc.date.available2017-04-13T12:03:13Z
dc.date.issued2016-11-01
dc.date.updated2017-04-13T12:03:13Z
dc.description.abstractBACKGROUND: BRAF and NRAS mutation detection is crucial for advanced melanoma treatment. Our aim was to evaluate how different characteristics from formalin-fixed paraffin-embedded (FFPE) samples, age of the block or DNA concentration could influence the success of BRAF and NRAS mutational screening. METHODS: DNA was obtained from 144 FFPE samples (62 primary melanoma, 43 sentinel lymph nodes [SLN] and 39 metastasis). BRAF and NRAS were sequenced by Sanger sequencing. RESULTS: Complete sequencing results were obtained from 75% (108/144) of the samples, and at least one gene was sequenced in 89% (128/144) of them. BRAF was mutated in 55% (29/53) and NRAS in 11% (5/45) of the primary melanomas sequenced. DNA concentration correlated with the tumor area used for DNA extraction (mm2) (adj p-value<0.01, r=0.73). The age of the block did not affect sequencing success. In 60% of samples kept for more than 10 years, both BRAF and NRAS were successfully sequenced. CONCLUSIONS: Preserving sufficient tumor area in FFPE blocks is important. It is necessary to keep the FFPE blocks, no matter their age, as they are necessary to decide the best treatment for the melanoma patient.
dc.format.extent6 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec668625
dc.identifier.issn1434-6621
dc.identifier.pmid27101548
dc.identifier.urihttps://hdl.handle.net/2445/109682
dc.language.isoeng
dc.publisherWalter de Gruyter GmbH & Co. KG.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1515/cclm-2015-1048
dc.relation.ispartofClinical Chemistry and Laboratory Medicine, 2016, vol. 54, num. 11, p. 1733-1738
dc.relation.urihttps://doi.org/10.1515/cclm-2015-1048
dc.rights(c) Walter de Gruyter GmbH & Co. KG., 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Fonaments Clínics)
dc.subject.classificationMelanoma
dc.subject.classificationTumors
dc.subject.classificationMutació (Biologia)
dc.subject.otherMelanoma
dc.subject.otherTumors
dc.subject.otherMutation (Biology)
dc.titleTime and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
668625.pdf
Mida:
302.64 KB
Format:
Adobe Portable Document Format